management of patients with hfref

PPTX 34 стр. 28,6 МБ Бесплатная загрузка

34 стр.

FaylHub.uz

Скачать через Telegram

Размер 28,6 МБ

Тип файла PPTX

Страницы 34

Обновлено Дек 2025

Предварительный просмотр (5 стр.)

Прокрутите вниз 👇

1 / 34

prezentatsiya powerpoint management of patients with hfref akbarali saidov symptoms are feelings or sensations a person has, whereas signs are observable characteristics a symptom is a manifestation of disease apparent to the patient himself, while a sign is a manifestation of disease that the physician perceives signs are objective and externally observable; symptoms are a person's reported subjective experiences omt = optimal medical therapy (class i recommended medical therapies for at least 3 months) some ace-i (or arb) is better than no ace-i some beta-blocker is better than no beta-blocker initiation of sacubitril/valsartan in ace-i naive (i.e. de novo) patients with hfref may be considered (iib, b). crt implantation case female 51 y.o. dcm. hfref. implantation pm 2023 (sss) ef 32% bisoprolol 10 mg eplerenone 50 mg sacubitril/valsartan 400 mg empagliflozin coronary angiography rca lca target cardiac vein lao rao be ap3 ap4 image1.emf image2.emf image3.emf image4.png image5.png image6.emf image7.emf …

2 / 34

$educed ejection fraction, mildly reduced ejection fraction and preserved ejection fraction hf = heart failure; hfmref = heart failure with mildly reduced ejection fraction; hfpef = heart failure with preserved ejection fraction; hfref = heart failure with reduced ejection fraction; lv = left ventricle; lvef = left ventricular ejection fraction. a signs may not be present in the early stages of hf (especially in hfpef) and in optimally treated patients. b for the diagnosis of hfmref, the presence of other evidence of structural heart disease (e.g. increased left atrial size, lv hypertrophy or echocardiographic measures of impaired lv filling) makes the diagnosis more likely. c for the diagnosis of hfpef, the greater the number of abnormalities present, the higher the likelihood of hfpef. www.escardio.org/guidelines ©esc 39 2021 esc guidelines for the diagnosis and treatment of acute and chronic heart failure (european heart journal 2021 – doi:10.1093/eurheartj/ehab368) therapeutic algorithm of class …$

3 / 34

roid function, fasting glucose and hba1c, lipids, iron status (tsat and ferritin) i c recommended diagnostic tests in all patients with suspected chronic heart failure bnp = b-type natriuretic peptide; ecg = electrocardiogram; hba1c = glycated haemoglobin; nt-probnp = n-terminal pro-b-type natriuretic peptide; tsat = transferrin saturation. a references are listed in section 4.2 for this item. www.escardio.org/guidelines ©esc 2021 esc guidelines for the diagnosis and treatment of acute and chronic heart failure (european heart journal 2021 – doi:10.1093/eurheartj/ehab368) recommendations class level an ace-i is recommended for patients with hfref to reduce the risk of hf hospitalization and death. i a a beta-blocker is recommended for patients with stable hfref to reduce the risk of hf hospitalization and death. i a an mra is recommended for patients with hfref to reduce the risk of hf hospitalization and death . i a dapagliflozin or empagliflozin are recommended for patients with hfref …

4 / 34

$commended to reduce the risk of hf hospitalization and cv death in symptomatic patients unable to tolerate an ace-i or arni (patients should also receive a beta-blocker and an mra). i b other pharmacological treatments indicated in selected patients with nyha class ii-iv heart failure with reduced ejection fraction (lvef ≤40%) (1) ace-i = angiotensin-converting enzyme inhibitor; arb = angiotensin-receptor blocker; arni = angiotensin receptor-neprilysin inhibitor; cv = cardiovascular; hf = heart failure; hfref = heart failure with reduced ejection fraction; mra = mineralocorticoid receptor antagonist; nyha= new york heart association. a the arbs with evidence in hfref are candesartan, losartan, and valsartan. www.escardio.org/guidelines ©esc 2021 esc guidelines for the diagnosis and treatment of acute and chronic heart failure (european heart journal 2021 – doi:10.1093/eurheartj/ehab368) recommendations class level i f -channel inhibitor ivabradine should be considered in symptomatic patients with lvef ≤35%, in sr and a resting heart rate ≥70 …$

5 / 34

sr = sinus rhythm. www.escardio.org/guidelines ©esc 2021 esc guidelines for the diagnosis and treatment of acute and chronic heart failure (european heart journal 2021 – doi:10.1093/eurheartj/ehab368) recommendations class level soluble guanylate cyclase stimulator vericiguat may be considered in patients in nyha class ii-iv who have had worsening hf despite treatment with an ace-i (or arni), a beta-blocker and an mra to reduce the risk of cv mortality or hf hospitalization. iib b hydralazine and isosorbide dinitrate hydralazine and isosorbide dinitrate should be considered in self-identified black patients with lvef ≤35% or with an lvef <45% combined with a dilated left ventricle in nyha class iii-iv despite treatment with an ace-i (or arni), a beta-blocker and an mra to reduce the risk of hf hospitalization and death. iia b hydralazine and isosorbide dinitrate may be considered in patients with symptomatic hfref who cannot tolerate any of an ace-i, an arb, or …

Хотите читать дальше?

Скачайте все 34 страниц бесплатно через Telegram.

Скачать полный файл

О "management of patients with hfref"

prezentatsiya powerpoint management of patients with hfref akbarali saidov symptoms are feelings or sensations a person has, whereas signs are observable characteristics a symptom is a manifestation of disease apparent to the patient himself, while a sign is a manifestation of disease that the physician perceives signs are objective and externally observable; symptoms are a person's reported subjective experiences omt = optimal medical therapy (class i recommended medical therapies for at least 3 months) some ace-i (or arb) is better than no ace-i some beta-blocker is better than no beta-blocker initiation of sacubitril/valsartan in ace-i naive (i.e. de novo) patients with hfref may be considered (iib, b). crt implantation case female 51 y.o. dcm. hfref. implantation pm 2023 (sss) ef …

Этот файл содержит 34 стр. в формате PPTX (28,6 МБ). Чтобы скачать "management of patients with hfref", нажмите кнопку Telegram слева.

Теги: management of patients with hfr… PPTX 34 стр. Бесплатная загрузка Telegram